ReportWire

IMTX Stock Price | Immatics N.V. Stock Quote (U.S.: Nasdaq) | MarketWatch

[ad_1]

Immatics N.V.

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

[ad_2]

Source link